Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial

PURPOSE: Adrecizumab, a non-neutralizing antibody of adrenomedullin (ADM) was recently investigated regarding its potential to restore endothelial barrier function in septic shock patients with high plasma ADM levels. Circulating dipeptidyl peptidase 3 (cDPP3), a protease involved in the degradation...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lier, Dirk, Picod, Adrien, Marx, Gernot, Laterre, Pierre-François, Hartmann, Oliver, Knothe, Claudia, Azibani, Feriel, Struck, Joachim, Santos, Karine, Zimmerman, Jens, Bergmann, Andreas, Mebazaa, Alexandre, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751049/
https://www.ncbi.nlm.nih.gov/pubmed/36530868
http://dx.doi.org/10.3389/fmed.2022.1058235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751049/
https://www.ncbi.nlm.nih.gov/pubmed/36530868
http://dx.doi.org/10.3389/fmed.2022.1058235

Ejemplares similares